Literature DB >> 21656114

[Systemic treatment of cutaneous lymphomas].

C-D Klemke1.   

Abstract

The management of patients with primary cutaneous lymphomas requires first of all a diagnostic work-up in order to differentiate between patients with nodal non-Hodgkin lymphomas with cutaneous manifestations and those with primary cutaneous lymphomas. In the latter an exact diagnosis of the type of cutaneous lymphoma has to be determined due to varying prognoses between the types of primary cutaneous lymphomas. In general, cutaneous lymphoma patients in early stages of disease can be treated successfully with skin-directed therapies. More advanced stages and some aggressive types like primary cutaneous diffuse large B-cell lymphoma, leg type or the leukemic variant of cutaneous T-cell lymphoma, the Sézary syndrome, require systemic treatment. The current recommendations regarding systemic therapy of patients with primary cutaneous lymphomas are reviewed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21656114     DOI: 10.1007/s00105-010-2043-3

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  59 in total

1.  No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sézary syndrome.

Authors:  Jeanette Lundin; Ben Kennedy; Claire Dearden; Martin J S Dyer; Anders Osterborg
Journal:  Blood       Date:  2005-05-15       Impact factor: 22.113

2.  Short German guidelines: cutaneous lymphomas.

Authors:  Rudolf Stadler; Chalid Assaf; Claus-Detlev Klemke; Dorothee Nashan; Michael Weichenthal; Reinhard Dummer; Wolfram Sterry
Journal:  J Dtsch Dermatol Ges       Date:  2008-05       Impact factor: 5.584

3.  Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma.

Authors:  E Olsen; M Duvic; A Frankel; Y Kim; A Martin; E Vonderheid; B Jegasothy; G Wood; M Gordon; P Heald; A Oseroff; L Pinter-Brown; G Bowen; T Kuzel; D Fivenson; F Foss; M Glode; A Molina; E Knobler; S Stewart; K Cooper; S Stevens; F Craig; J Reuben; P Bacha; J Nichols
Journal:  J Clin Oncol       Date:  2001-01-15       Impact factor: 44.544

4.  Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients.

Authors:  H S Zackheim; M Kashani-Sabet; S T Hwang
Journal:  J Am Acad Dermatol       Date:  1996-04       Impact factor: 11.527

5.  Combination therapy with extracorporeal photopheresis, interferon-alpha, PUVA and topical corticosteroids in the management of Sézary syndrome.

Authors:  Nina Booken; Christel Weiss; Jochen Utikal; Moritz Felcht; Sergij Goerdt; Claus-Detlev Klemke
Journal:  J Dtsch Dermatol Ges       Date:  2010-02-18       Impact factor: 5.584

Review 6.  WHO-EORTC classification for cutaneous lymphomas.

Authors:  Rein Willemze; Elaine S Jaffe; Günter Burg; Lorenzo Cerroni; Emilio Berti; Steven H Swerdlow; Elisabeth Ralfkiaer; Sergio Chimenti; José L Diaz-Perez; Lyn M Duncan; Florent Grange; Nancy Lee Harris; Werner Kempf; Helmut Kerl; Michael Kurrer; Robert Knobler; Nicola Pimpinelli; Christian Sander; Marco Santucci; Wolfram Sterry; Maarten H Vermeer; Janine Wechsler; Sean Whittaker; Chris J L M Meijer
Journal:  Blood       Date:  2005-02-03       Impact factor: 22.113

7.  Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.

Authors:  Elise A Olsen; Youn H Kim; Timothy M Kuzel; Theresa R Pacheco; Francine M Foss; Sareeta Parker; Stanley R Frankel; Cong Chen; Justin L Ricker; Jean Marie Arduino; Madeleine Duvic
Journal:  J Clin Oncol       Date:  2007-06-18       Impact factor: 44.544

8.  Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome.

Authors:  Jeanette Lundin; Hans Hagberg; Roland Repp; Eva Cavallin-Ståhl; Susanne Fredén; Gunnar Juliusson; Eija Rosenblad; Geir Tjønnfjord; Tom Wiklund; Anders Osterborg
Journal:  Blood       Date:  2003-01-23       Impact factor: 22.113

9.  Cutaneous lymphomas in Germany: an analysis of the Central Cutaneous Lymphoma Registry of the German Society of Dermatology (DDG).

Authors:  Chalid Assaf; Sylke Gellrich; Matthias Steinhoff; Dorothée Nashan; Franca Weisse; Edgar Dippel; Esther Coors; Anette Stein; Philippa Gollin; Ulrike Henke; Sabrina Adam-Murati; André Koch; Claus-Detlev Klemke; Rudolf Stadler; Wolfram Sterry
Journal:  J Dtsch Dermatol Ges       Date:  2007-08       Impact factor: 5.584

10.  Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patients.

Authors:  J Valencak; F Weihsengruber; K Rappersberger; F Trautinger; A Chott; B Streubel; L Muellauer; M Der-Petrossian; C Jonak; M Binder; M Raderer
Journal:  Ann Oncol       Date:  2008-10-03       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.